Author

B. Gordon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:clustering· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

K. Blankenship· 3 shared M. A. Dyer· 3 shared A. Karlstrom· 2 shared E. Stewart· 2 shared J. McEvoy· 2 shared M. R. Clay· 2 shared P. Geeleher· 2 shared X. Zhou· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. Blankenship

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Preclinical Pediatric Molecular Analysis for Therapy Choice (MATCH)

K. Blankenship, T.-C. Chang, Y. Fan, B. Gordon, W. C. Wright, M. Kieffer, A. Karlstrom, J. Jeon, A. Patel, J. Dapper, W. V. Caufield, B. B. Freeman, S. Federico, M. R. Clay, G. G. Wu, , E. A. Stewart

This paper establishes a diverse collection of preclinical models for pediatric solid tumors and demonstrates their utility in precision medicine trials and drug testing.

bioRxiv · Jul 22, 2024 · PreprintCancer Biology

Paridiprubart inhibits TLR4-dependant NF-κB activation by multiple pathogens

R. Malty, R. Hilbe, S. Ahn, L. Kesselman, J. Lam, K. Kasawara, L. Costa, N. Rajakulendran, B. Gordon, M. Brooks, S. Mubareka, I. Tancevski, S. D. Gray-Owen

This study shows that paridiprubart, a TLR4 inhibitor, suppresses NF-κB activation by multiple pathogens including SARS-CoV-2 and bacterial agents.

bioRxiv · Jun 27, 2023 · PreprintImmunology

The Myogenesis Program Drives Clonal Selection and Drug Resistance in Rhabdomyosarcoma

A. G. Patel, X. Chen, X. Huang, M. R. Clay, N. Komarova, M. J. Krasin, A. Pappo, H. Tillman, B. A. Orr, J. McEvoy, B. Gordon, K. Blankenship, C. Reilly, X. Zhou, J. L. Norrie, , M. A. Dyer

This study shows that targeting developmental states in rhabdomyosarcoma can prevent disease recurrence by eliminating myoblast-like cells and inhibiting EGFR-dependent paraxial mesoderm populations.

bioRxiv · Jun 16, 2021Cancer Biology

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

bioRxiv · Feb 25, 2021Cancer Biology

nkx3.2 mutant zebrafish accommodate jaw joint loss through a phenocopy of the head shapes of Paleozoic jawless fish

T. Miyashita, P. Baddam, J. Smeeton, A. P. Oel, N. Natarajan, B. Gordon, A. R. Palmer, G. Crump, D. Graf, W. T. Allison

This paper shows that nkx3.2 mutant zebrafish develop skull shapes similar to ancient jawless fish due to jaw joint loss, indicating functional constraints on skull morphology.

bioRxiv · Oct 18, 2019Evolutionary Biology